J&J Just Locked Down a $5 Billion Drug Until 2035. Generics Can't Touch It.

Sandoz sent its notice letter to Janssen (J&J's pharma subsidiary) on April 17, 2023. Janssen fired back with a lawsuit on May 31, 2023, in the District of Delaware. The battle was on.

Five Days, One Decade

The case went to trial in February 2026. After five days of proceedings and months of post-trial briefing, the court sided completely with Janssen. The judge found that Sandoz's proposed generic would infringe J&J's patents and that those patents were not invalid.

Sandoz had argued two main defenses. First, that its product wouldn't actually infringe the asserted patents (U.S. Patent Nos. 11,446,260; 10,869,844; 11,173,134; and 11,311,500, among others). Second, that the patents themselves were invalid under sections of patent law dealing with obviousness and inadequate description. The court rejected both arguments.

The opinion itself was sealed, so the public doesn't get to see the judge's detailed reasoning. But the bottom line is crystal clear: no generic Spravato before September 2035.

Why Generics Companies Should Be Nervous

This ruling isn't just about one drug. It sends a signal to every generics company thinking about challenging CNS patents.

J&J's Spravato patent portfolio is a textbook example of layered protection. The company holds patents expiring in 2027, 2031, 2034, and 2035, according to secondary reporting on Orange Book listings. Even if a generics company successfully knocked out one patent, others would still block market entry. It's like a castle with multiple walls: breach one and you've still got three more to deal with.

And the broader Hatch-Waxman landscape isn't exactly friendly to generics challengers right now. A 2024 review found that 283 Hatch-Waxman litigations were resolved or terminated that year, with brand-name companies prevailing far more often than generics. Courts have also shown a willingness to grant broad protections to innovators, even as the Federal Circuit pushes back on the most extreme injunctions.

For companies like Hikma, Alkem, and others that may have been eyeing their own generic esketamine filings, this ruling is a neon-lit warning sign.

The Moat Around the Castle

Even without the patent victory, Spravato would be hard to compete with. The drug is distributed through a REMS program (Risk Evaluation and Mitigation Strategy), which means it can only be administered in certified healthcare settings under medical supervision. Patients can't just pick it up at CVS.

That supervised-delivery requirement creates enormous logistical hurdles for any competitor. You need certified sites, trained staff, and monitoring protocols. It's one of the reasons generic competition was always going to be tougher here than with, say, a simple pill.

Spravato's biggest practical rival right now isn't a generic at all. It's IV ketamine administered in private clinics, which is widely available but usually paid out of pocket. For patients with insurance coverage, Spravato remains the path of least resistance.

The Bottom Line

J&J just bought itself nearly a decade of uncontested growth on a drug that could become a $5 billion franchise. Sandoz spent three years and untold legal fees only to walk away empty-handed. The sealed opinion means we may never learn exactly why the court found the patents valid and infringed, which makes it even harder for the next generics challenger to learn from Sandoz's mistakes.

For patients with treatment-resistant depression, a generic version of Spravato would have meant lower costs and broader access. That conversation is now on hold until 2035.

And for generics companies? The message is simple: if you're going to pick a fight with a well-fortified patent portfolio, you'd better bring more than a Paragraph IV certification. You'd better bring a battering ram.

Exelixis Was Three Months From an Answer. Then the FDA Hit Pause.

The FDA just pushed back its decision on Exelixis' colorectal cancer combo by three months, and analysts are surprised. With tightening regulatory standards for combination oncology drugs and a crowded competitive landscape, the stakes of this delay go well beyond one company's pipeline.